Von Hippel Lindau/VHL Antibody (VHL40): sc-135657

VHL Antibody (VHL40) is a mouse monoclonal IgG1 kappa light chain antibody that detects VHL protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. anti-VHL antibody (VHL40) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. VHL protein plays a crucial role as a tumor suppressor, and dysfunction is linked to von Hippel-Lindau syndrome, which predisposes individuals to several tumor types, including renal cell carcinoma, hemangioblastomas, and pheochromocytomas. VHL protein is primarily located in the cytoplasm and nucleus, where VHL interacts with the Elongin (SIII) complex, a heterotrimeric protein complex essential for regulating gene transcription. By binding to the Elongin B and C subunits, VHL protein inhibits the transcriptional activity of this complex, thereby playing a vital role in cellular processes such as oxygen sensing and the regulation of hypoxia-inducible factors. Different isoforms of VHL protein, resulting from alternatively spliced transcript variants, highlight the complexity of regulation and function, with variations in molecular weight observed across species.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Von Hippel Lindau/VHL Antibody (VHL40) References:

1. Loss of heterozygosity on 3p in a renal cell carcinoma in von Hippel-Lindau syndrome.  |  Decker, HJ., et al. 1989. Cancer Genet Cytogenet. 39: 289-93. PMID: 2568884
2. Specific genetic change in tumors associated with von Hippel-Lindau disease.  |  Tory, K., et al. 1989. J Natl Cancer Inst. 81: 1097-101. PMID: 2738940
3. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma.  |  Seizinger, BR., et al. 1988. Nature. 332: 268-9. PMID: 2894613
4. Role of SOCS and VHL Proteins in Neuronal Differentiation and Development.  |  Kanno, H., et al. 2023. Int J Mol Sci. 24: PMID: 36835292
5. FBXO22 promotes glioblastoma malignant progression by mediating VHL ubiquitination and degradation.  |  Shen, Z., et al. 2024. Cell Death Discov. 10: 151. PMID: 38519492
6. Potency-Enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability.  |  Wu, H., et al. 2024. J Med Chem. 67: 8585-8608. PMID: 38809766
7. Tumor suppression and transcription elongation: the dire consequences of changing partners.  |  Krumm, A. and Groudine, M. 1995. Science. 269: 1400-1. PMID: 7660121
8. Inhibition of transcription elongation by the VHL tumor suppressor protein.  |  Duan, DR., et al. 1995. Science. 269: 1402-6. PMID: 7660122
9. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II.  |  Aso, T., et al. 1995. Science. 269: 1439-43. PMID: 7660129
10. Molecular cloning of an essential subunit of RNA polymerase II elongation factor SIII.  |  Garrett, KP., et al. 1994. Proc Natl Acad Sci U S A. 91: 5237-41. PMID: 8202474
11. Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene.  |  Gross, DJ., et al. 1996. J Clin Endocrinol Metab. 81: 147-9. PMID: 8550742
12. Frequent allelic loss at chromosome arm 3p is distinct from genetic alterations of the Von-Hippel Lindau tumor suppressor gene in head and neck cancer.  |  Waber, PG., et al. 1996. Oncogene. 12: 365-9. PMID: 8570213

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Von Hippel Lindau/VHL Antibody (VHL40) has 28 citations in a variety of scientific publications.

Primary antibodies like Anti-Von Hippel Lindau/VHL Antibody (VHL40) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Von Hippel Lindau/VHL Antibody (VHL40) Specifications

Alternate Product Name: von Hippel-Lindau tumor suppressor

Product Clone Name: VHL40

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 54-213

Epitope Target: VHL

Epitope Species: human

Product Reactivity/Detection: VHL

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 28 citations in various scientific publications

Available Conjugates/Forms for Von Hippel Lindau/VHL Antibody (VHL40): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin